Last reviewed · How we verify
Deoxyadrenaline
Deoxyadrenaline, marketed by Fujian Medical University Union Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may provide a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Deoxyadrenaline |
|---|---|
| Sponsor | Fujian Medical University Union Hospital |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia (PHASE4)
- Effect of Cerebral Oxygen Saturation Monitoring on POCD of Elderly Patients Undergoing Shoulder Arthroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deoxyadrenaline CI brief — competitive landscape report
- Deoxyadrenaline updates RSS · CI watch RSS
- Fujian Medical University Union Hospital portfolio CI